This article is more than 5 years old. Information may no longer be current.
DEB demonstrated better healing characteristics in in-stent restenosis than EES
Click Here to Manage Email Alerts
Drug-eluting balloons yielded improved healing characteristics but with slightly less efficacy than drug-eluting stents in a cohort of patients who underwent implantation to treat in-stent restenosis, results of an optical coherence tomography study concluded.
The aim of the study was to provide further information about the healing characteristics of a paclitaxel-eluting balloon (SeQuent Please, B. Braun Melsungen AG) vs. everolimus-eluting stents (EES; Xience V/Prime, Abbott Vascular) for the treatment of in-stent restenosis in bare-metal stents, according to the researchers. They used OCT to assess 50 patients with BMS in-stent restenosis.
The proportion of patients with uncovered struts at 9 months served as the primary outcome measure.
Patients were randomly assigned implantation with a paclitaxel-eluting balloon or EES. The final analysis included 366 ± 135 struts per patient in the DEB group and 636 ± 184 struts per patient in the stent group.
The rate of uncovered struts was 1.4% in the balloon group compared with 3.1% in the stent group (P=.025).
Patients in the DEB group demonstrated a mean neointimal hyperplasia area of 2.4 ± 1.08 mm2 compared with 1.92 ± 0.67 mm2 in EES (P=.1806). The proportion of malapposed struts was low in both the DEB (0.2%) and DES (0.3%; P=.699) groups.
Other results at 9 months demonstrated that minimum lumen diameter was lower in the DEB group (2.13 vs. 2.54 mm; P=.006). Diameter stenosis was higher in the DEB group than in the DES group at this time point (26.4% vs. 11.4%; P=.002), as was late lumen loss (0.28 mm vs. 0.07 mm; P=.1).
Mortality, target lesion revascularization and stent thrombosis rates were similar in both groups at 1 year, according to the findings.
“DEB appears to be associated with better healing characteristics, as assessed by stent strut coverage with OCT, but tended to be slightly less effective compared to EES,” the researchers concluded. “These findings give support to the use of either DEB or EES as valuable treatment options for [in-stent restenosis].”
Disclosure: The researchers report associations with Abbott Vascular and B. Braun Melsungen AG.
Click Here to Manage Email Alerts